The pharmacogenomics of warfarin: Closing in on personalized medicine

Molecular Interventions

Volumn 6, Issue 4, 2006, Pages 223-227

  Rettie, Allan E ^a   Tai, Guoying ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; COUMARIN ANTICOAGULANT; CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

AMINO ACID SUBSTITUTION; ANTICOAGULANT THERAPY; BLEEDING; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MISSENSE MUTATION; PHARMACOGENOMICS; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; THROMBOSIS PREVENTION; DOSE RESPONSE; GENETICS; METABOLISM; MUTATION; PHARMACOGENETICS; PHYSIOLOGY;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIXED FUNCTION OXYGENASES; MUTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 33749008249     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.6.4.8     Document Type: Review

References (31)

1. Kresge, N., Simoni, R.D., and Hill, R.L. Hemorrhagic sweet clover disease, dicumarol, and warfarin: The work of Karl Paul Link. J. Biol. Chem. 280, e5-e6 (2005). Succinct historical perspective on warfarin's development as an anticoagulant.
2. Shapiro, S.S. Treating thrombosis in the 21st century. N. Engl. J. Med. 349, 1762-1764 (2003).
3. Eichelbaum, M., Ingelman-Sundberg, M., and Evans, W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006). Informative review on personalized medicine.
4. Marsh, S. and McLeod, H.L. Pharmacogenomics: From bedside to clinical practice. Hum. Mol. Genet. 15 Spec No 1, R89-R93 (2006).
5. Wajih, N., Sane, D.C., Hutson, S.M., and Wallin, R. Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: Evidence for a functional CXXC redox center in the system. J. Biol. Chem. 280, 10540-10547 (2005).
6. Fasco, M.J. and Principe, L.M. R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. J. Biol. Chem. 257, 4894-4901 (1982).
7. Li, T., Chang, C.Y., Jin, D.Y., Lin, P.J., Khvorova, A., and Stafford, D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004). Seminal report of the discovery of the warfarin target gene.
8. Rost, S., Fregin, A., Ivaskevicius, V. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004). Seminal report of the link between VKORC1 polymorphisms and warfarin resistance.
9. Rieder, M. J., Reiner, A.P., Gage, B.F. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005). Delineation of VKORC1 haplotypes, their association with warfarin dose and underlying mechanism.
10. Bodin, L., Verstuyft, C., Tregouet, D.A. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106, 135-140 (2005).
11. D'Andrea, G., D'Ambrosio, R.L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E., and Margaglione, M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
12. Lee, S.C., Ng, S.S., Oldenburg, J. et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79, 197-205 (2006).
13. Takahashi, H., Wilkinson, G.R., Nutescu, E.A. et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006).
14. Veenstra, D.L., You, J.H., Rieder, M.J., Farin, F.M., Wilkerson, H.W., Blough, D.K., Cheng, G., and Rettie, A.E. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15, 687-691 (2005).
15. Rettie, A.E., Korzekwa, K.R., Kunze, K.L., Lawrence, R.F., Eddy, A.C., Aoyama, T., Gelboin, H.V., Gonzalez, F.J., Trager, W.F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992). Identification of CYP2C9 as the major human P450 enzyme mediating metabolism of S-warfarin.
16. Yasar, U., Eliasson, E., Dahl, M.L., Johansson, I., Ingelman-Sundberg, M., and Sjoqvist, F. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun. 254, 628-631 (1999).
17. Rettie, A.E., Haining, R.L., Bajpai, M., and Levy, R.H. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 35, 253-255 (1999).
18. Rettie, A.E. and Jones, J.P. Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 45, 477-494 (2005).
19. Xie, H.G., Prasad, H.C., Kim, R.B., and Stein, C.M. CYP2C9 allelic variants: Ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54, 1257-1270 (2002). Excellent review of the influence of ethnicity on CYP2C9 function.
20. Kidd, R.S., Curry, T.B., Gallagher, S., Edeki, T., Blaisdell, J., and Goldstein, J.A. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11, 803-808 (2001).
21. Yasar, U., Aklillu, E., Canaparo, R., Sandberg, M., Sayi, J., Roh, H.K., and Wennerholm, A. Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur. J. Clin. Pharmacol. 58, 555-558 (2002).
22. Ieiri, I., Tainaka, H., Morita, T. et al. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther. Drug Monit. 22, 237-244 (2000).
23. Guo, Y., Zhang, Y., Wang, Y., Chen, X., Si, D., Zhong, D., Fawcett, J.P., and Zhou, H. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab. Dispos. 33, 749-753 (2005).
24. Maekawa, K., Fukushima-Uesaka, H., Tohkin, M.et al. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet. Genomics 16, 497-514 (2006).
25. Wiwanitkit, V. Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations. Clin. Appl. Thromb. Hemost. 12, 219-222 (2006).
26. Sanderson, S., Emery, J., and Higgins, J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet systematic review and meta-analysis. Genet. Med. 7, 97-104 (2005). Meta-analysis of studies evaluating the effect of CYP2C9 alleles on anticoagulation-related outcomes.
27. Visser, L.E., van Schaik, R.H., van Vliet, M., Trienekens, P.H., De Smet, P.A., Vulto, A.G., Hofman, A., van Duijn, C.M., and Stricker, B.H. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb. Haemost. 92, 61-66 (2004).
28. Reitsma, P.H., van der Heijden, J.F., Groot, A.P., Rosendaal, F.R., and Büller, H.R. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2, e312 (2005).
29. Harrington, D.J., Underwood, S., Morse, C., Shearer, M.J., Tuddenham, E.G., Mumford, and A.D. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb. Haemost. 93, 23-6 (2005).
30. Bodin, L., Horellou, M.H., Flaujac, C., Loriot, M.A., and Samama, M.M. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J. Thromb. Haemost. 3, 1533-1535 (2005).
31. Le Bonniec, B. La cible de la warfarine indentifieé. Med Sci (Paris) 20, 512-514 (2004).